• About
    • Corporate Overview
    • Management Team
    • Partnerships
    • Compliance and ethics
  • Products
    • Pipeline
    • Our Medicine
    • Tivozanib
    • Ficlatuzumab
    • AV-203
    • AV-380
    • AV-353
    • Expanded Access Policy
  • Publications & Presentations
  • Media
    • Press Releases
    • Media Toolkit
  • Life at AVEO
    • Overview
    • Job Openings
  • Contact

Prrx1 isoform switching regulates pancreatic cancer invasion and metastatic onization

Authors: Shigetsugu Takano,1,2,3,4 Maximilian Reichert,1,2,3,5 Basil Bakir,1,2,3 Koushik K. Das,1,2,3 Takahiro Nishida,4 Masaru Miyazaki,4 Steffen Heeg,1,2,3,6 Meredith A. lins,1,2,3 BenoĆ®t Marchand,1,2,3 Philip D. Hicks,1,2,3 Anirban Maitra,7,8 and Anil K. Rustgi1,2,3,9. Click here for link to article. Click here for link to Supplemental Text and Figures.

Click Here To View Our ASCO Poster:

TIVO-3: Final OS Analysis Of A Phase III, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib To Sorafenib In Subjects With Metastatic Renal Cell Carcinoma (RCC)

© 2012 AVEO Pharmaceuticals, Inc. All rights reserved.
Terms of Use Privacy Policy Cookie Policy Code of Business Conduct and Ethics
logo
  • About
    • Corporate Overview
    • Management Team
    • Partnerships
    • Compliance and ethics
  • Products
    • Pipeline
    • Our Medicine
    • Tivozanib
    • Ficlatuzumab
    • AV-203
    • AV-380
    • AV-353
    • Expanded Access Policy
  • Publications & Presentations
  • Media
    • Press Releases
    • Media Toolkit
  • Life at AVEO
    • Overview
    • Job Openings
  • Contact